CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for Voyager Therapeutics, Inc. (VYGR)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for VYGR, mapped to public ticker VYGR (CIK 0001640266). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingVYGR55% conf

Voyager Therapeutics, Inc. (VYGR) — PHASE2 primary completion 21 days ago (readout window)

Upstream (observed)
Clinical trial status (PHASE2) — VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗
Trial → FilingVYGR35% conf

Voyager Therapeutics, Inc. (VYGR) — PHASE1 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE1) — An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →